The Eighth Annual International Employment Survey - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

The Eighth Annual International Employment Survey

Pharmaceutical Technology

For some people, the statistics say it all: a growing salary, good benefits, daily intellectual challenges, and job security. Others gain a better perspective by looking closely at more subjective issues such as job environment, communication, and support from management.

Pharmaceutical Technology's 2005 employment report presents both sides. Thanks to the more than 2100 survey participants (our highest response yet), we highlight the issues directly affecting workers in the pharmaceutical industry, including demographic information, education and work experience, salary and benefits, and attitudes toward current employment. New this year, the survey portrays the effects on industry jobs of several federal guidelines and initiatives, and employees had an opportunity to sound off about the greatest satisfactions and frustrations of their work.

Table I: Results overview—profile of a typical industry employee.
Most results are representative of all responses, regardless of participants' locations. Some salary results are presented for US employees only. When reviewing salary and benefits information, readers should take into account a region's cost of living and economy as well as the wide range of experience, job functions, and educational certification represented. No single statistic should be used for comparison without taking these factors into account.

Methodology and statistics

The September 2005 questionnaire, posted on, received 2178 responses. Of these, 79% were received from industry workers in the United States, including Puerto Rico. Some overall results are summarized in Table I, with details provided in this article.


Figure 1: Survey participants by sex.
Sex and age. Of the total number of responses, 70% overall were from men (see Figure 1). The average respondent age is 43 years.

Work location. As noted, 79% of respondents work in the United States. Of these, approximately 10% each work in California and New Jersey; 7% in Pennsylvania; 5% each in New York, North Carolina, and Massachusetts; 4% each in Illinois and Indiana; and ~2.5% each in Michigan and Puerto Rico. All other states each accounted for less than 2% of the total US responses.

Workers also responded from the United Kingdom (4%), Canada (3.4%), and Ireland (1.4%) as well as Germany, India, Italy, Belgium, The Netherlands, and Switzerland (~1% each). Other regions represented less than 1% each of the total number of responses.

Readers should take into account the number of responses received from each region when noting the results of this survey, especially salary results according to US region.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here